# Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis

> **NCT06449001** · PHASE3 · RECRUITING · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 6 (estimated)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria
- PNH
- Extravascular Hemolysis

## Interventions

- **DRUG:** Danicopan

## Key facts

- **NCT ID:** NCT06449001
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-11
- **Primary completion:** 2027-05-28
- **Final completion:** 2028-03-10
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2025-12-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06449001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06449001, "Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06449001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*